Sensus Healthcare 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Third-quarter 2026 revenue was $6 million, down 13% from $6.9 million in the 3rd quarter of 2025, primarily because of product mix and no sales to the historically largest customer.
- Sensus Healthcare shipped 26 systems, compared with 16 a year earlier; 8 shipments had been delayed from the 2nd quarter by 3rd-party financing delays, and 3 systems were shipped under Fair Deal Agreement or rental arrangements, with revenue recognized over the applicable agreement term.
- Cost of sales decreased to $2.7 million from $4.2 million, gross profit increased to $3.3 million from $2.7 million, and gross margin improved to approximately 55% from 39%, primarily because of system mix, including a greater proportion of higher-margin SRT-100 units.
- General and administrative expense was $2.3 million versus $1.9 million, sales and marketing expense was essentially flat at $1.5 million, and research and development expense decreased to $1.1 million from $1.8 million.
- Adjusted EBITDA was negative $1.5 million versus negative $2.4 million; net loss was $1.5 million, or $0.09 per share, compared with $0.9 million, or $0.06 per share, with the 3rd quarter of 2025 including an income tax benefit of approximately $1.5 million.
- At quarter end, Sensus had $12.9 million in cash, restricted cash, and cash equivalents, compared with $15.2 million at the end of June, no prepaid inventory, and no outstanding borrowings under its revolving line of credit.
- Sensus placed its 1,000th SRT system and secured initial system purchases from 2 large private equity-backed dermatology groups; one group chose to purchase and the other chose the Fair Deal Agreement.
- Management said it delivered more units directly to dermatology practices in Q3 than in the prior 2 quarters combined and that, excluding sales to its historically largest customer, revenue and gross margins increased year over year and quarter over quarter.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Please note, this event is being recorded. I would now like to turn the conference over to Leigh Salvo, Investor Relations. Please go ahead. Thank you.
Good afternoon, and thank you all for joining today's call to discuss Sensus Healthcare's third quarter 2026 financial results. Joining me from Sensus are Joe Sardano, Chairman and Chief Executive Officer, Michael Sardano, President, Chief Commercial Officer, and General Counsel, and Javier Rampolla, Chief Financial Officer. As a reminder, some of the matters that will be discussed during today's call contain forward-looking statements within the meaning of federal securities laws. All statements other than historical facts that address activities Sensus Healthcare assumes, plans, expects, believes, intends, or anticipates, and other similar expressions, will, should, or may occur in the future, are forward-looking statements. The forward-looking statements are management's beliefs based on currently available information as of the date of this conference call, November 12, 2026. Sensus Healthcare undertakes no obligation to revise or update any forward-looking statements, except as required by law.
All forward-looking statements are subject to risks and uncertainties as described in the company's Forms 10-K, 10-Q, and other SEC filings. During today's call, references will be made to certain non-GAAP financial measures. Sensus believes these measures provide useful information for investors, yet they should not be considered a substitute for GAAP, nor should they be reviewed as a substitute for operating results determined in accordance with GAAP. A reconciliation of non-GAAP to GAAP results is included in today's press release. With that, I'd like to turn the call over to Joe Sardano.
Joe? Thank you, Lee, and good afternoon, everyone.
At the beginning of this year, we laid out five priorities for Sensus: educate the market about SRT and the new reimbursement environment, accelerate customer adoption, expand recurring revenue opportunities, broaden our commercial reach, and move Sensus towards sustainable profitability. Those priorities have not changed. I want to take a minute to start with the bigger picture because it's important to understand what we're building at Sensus. For decades, surgery, including Mohs surgery, has been a primary treatment option for non-melanoma skin cancer. Mohs is an effective and well-established procedure, but surgery isn't the right choice for every patient. Many patients want to avoid cutting, stitches, scarring, or the recovery associated with surgery, particularly when the cancer is in the cosmetically sensitive area. SRT gives physicians and patients another option. It's a non-invasive treatment that can address certain skin cancers without surgical excision.
We believe patients should understand their treatment choices, and physicians should have the technology to offer those choices when clinically appropriate. That is our Vision for Sensus. We are not simply selling equipment. We are working to make SRT a more widely understood and accessible treatment option. We are making progress. During the first half of the year, we concentrated on educating the market about the dedicated CPT codes and what the new reimbursement landscape means for physicians and their practices. Now we are seeing that groundwork translate into a stronger pipeline, more inbound interest and engagement with a broader range of customers, from independent dermatology practices to larger physician groups. To me, that is the real opportunity. We are building a broader, more diversified, and direct customer base, including organizations with the potential to bring SRT to multiple locations.
That is how we intend to build a business with a wider geographic reach and more sustainable, predictable growth. The dedicated CPT codes are an important part of that transition, giving physicians greater clarity about the economics of incorporating SRT into their practices. We have expanded those efforts beyond the physician community. Our recent launch of treatskincancer.com is designed to help patients better understand their options, including non-invasive alternatives, and have informed conversations with their physicians. Our ambitions extend beyond U.S. dermatology. We continue to pursue international opportunities, particularly in Asia Pacific, while exploring adjacent markets and applications where our technology offers value. Another important part of our strategy is what happens after a system is placed. As our installed base grows, we have opportunities to support greater treatment utilization and develop revenue streams through programs such as our Fair Deal Agreement and Sensus Link.
Over time, our goal is to combine equipment sales with software, services, and utilization-based revenue. We believe that can create a stronger, more scalable business. I also want to recognize a milestone on the specialty product. We recently placed our 1,000th SRT system. That represents years of building this company, developing the technology, and earning the trust of physicians. We are building a stronger, more diversified Sensus. We have the technology, the reimbursement framework, the commercial programs, and the expanding base of physicians who recognize the value of what we offer. Our focus is on bringing those pieces together to drive adoption, increase utilization, and build consistently growing profitable business. At the start of this year, we said that each quarter would be better than the previous one. In the next few minutes, Michael and Javier will highlight three areas that I believe clearly indicate our progress so far in 2026.
In short, we delivered more units directly to dermatology practices in Q3 than in the prior two quarters combined. In addition, excluding sales to our historically largest customer, both revenue and gross margins increased year-over-year and quarter-over-quarter. We expect to build on this momentum in the fourth quarter. Importantly, every system we place creates a revenue opportunity for Sensus, whether through an outright sale or recurring revenue generated over time through our alternative commercial models. With that, I will turn the call over to Michael to discuss our commercial activities in more detail.
Michael. Thank you, Joe. I'd like to start by giving some color on what we're seeing in the market, because the nature of our customer conversations in the United States has evolved considerably since the beginning of the year.
When the dedicated CPT codes took effect on January 1, our first job was education. Physicians needed to understand the codes, the economics, and most importantly, see reimbursement working in practice. That conversation is changing. Increasingly, we're no longer explaining whether reimbursement works. We're talking about how to bring SRT into their practices. We continue to support that process with physician education and training in the technology, treatment workflows, and system operation. Our pipeline strengthened during the third quarter through physician education, inbound inquiries, and follow-ups from our commercial initiatives.
We are seeing engagement across independent dermatology practices and larger physician groups, and we're increasingly spending time with organizations that have multiple locations. Those discussions can take longer than a single practice sale, but one relationship can ultimately create opportunities for multiple systems. During the quarter, we secured initial system purchases from two large private equity-backed dermatology groups. These new relationships illustrate the type of customer we are now reaching. Customers also have more ways to access our technology. They can purchase a system outright, use financing, enter a rental arrangement, or participate in our Fair Deal Agreement program. Those options allow us to meet practices where they are. We're seeing customers evaluate direct ownership as they better understand the reimbursement economics, while larger groups, in particular, may find our Fair Deal Shared Service model an attractive way to introduce SRT across multiple practices.
We are continuing to focus on increasing utilization within the Fair Deal Agreement program. That will allow us to participate in treatment activity as adoption expands. At the same time, we're continuing to develop Sensus Link and other software and service opportunities across our installed base. These initiatives are part of our longer-term strategy to complement equipment sales with recurring utilization-based revenue. On the patient side, we launched treatskincancer.com in September to help people learn about skin cancer treatment options, including non-invasive approaches, and to encourage informed conversations with their physicians. It complements the work we're doing with dermatologists. Early engagement included nearly 1,000 visits during the initial launch period and more than 2,000 social media views. Internationally, I spent a significant amount of time during the quarter developing opportunities across Asia Pacific, particularly in Australia, New Zealand, China, and Hong Kong.
During the fourth quarter, Sensus will additionally be attending conferences in Europe and Korea. We continue to see physician interest in SRT across these markets. China remains an important market for us, and the response we've seen in Australia has been especially encouraging. Australia and New Zealand have a substantial skin cancer burden, which underscores the potential need for additional treatment options, such as SRT. We're actively developing relationships that could support our commercial presence, and we intend to be disciplined as we pursue international expansion. Our priorities are straightforward: convert the pipeline, expand adoption across a broader customer base, increase utilization of systems already in the field, and give customers the flexibility to bring SRT into their practices. We have more opportunities in front of us today than at the beginning of the year. Now, it's about conversion. With that, I'll turn the call over to Javier for review of the financials.
Javier. Thank you, Michael, and good afternoon, everyone.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
7 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
